Home Newsfeeds Citigroup Initiates Coverage On Intuit with Buy Rating, Announces Price Target of $538

Citigroup Initiates Coverage On Intuit with Buy Rating, Announces Price Target of $538

Citigroup analyst Steven Enders initiates coverage on Intuit (NASDAQ:INTU) with a Buy rating and announces Price Target of $538.

byBenzinga Newsdesk

September 1, 2022

1 minute read

Citigroup analyst Steven Enders initiates coverage on Intuit (NASDAQ:INTU) with a Buy rating and announces Price Target of $538.

These Analysts Cut Their Forecasts On Target After Downbeat Earnings

By Avi Kapoor

May 23, 8:12 AM

Target Corp (NYSE:TGT) reported weaker-than-expected first-quarter earnings on Wednesday. The company reported a first-quarter FY24 sales decline of…

TGT

Analyst Ratings

Expert Ratings for Ansys

By Benzinga Insights

July 14, 5:00 PM

Ansys (NASDAQ:ANSS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

ANSS

JP Morgan Upgrades Avis Budget Gr to Overweight, Announces $231 Price Target

By Benzinga Newsdesk

October 24, 6:43 AM

JP Morgan analyst Ryan Brinkman upgrades Avis Budget Gr (NASDAQ:CAR) from Neutral to Overweight and announces $231 price target.

CAR

Better Therapeutics Completes Exploratory Trial For Fatty Liver Disease And Announces Topline Results; Co. Reports ‘Study Conducted with Arizona Liver Health Met Primary Endpoint’

By Benzinga Newsdesk

December 8, 8:04 AM

Study Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients Company Intends to Apply

BTTX

Citigroup Initiates Coverage On Intuit with Buy Rating, Announces Price Target of $538

Related Posts

These Analysts Cut Their Forecasts On Target After Downbeat Earnings

Expert Ratings for Ansys

JP Morgan Upgrades Avis Budget Gr to Overweight, Announces $231 Price Target

Better Therapeutics Completes Exploratory Trial For Fatty Liver Disease And Announces Topline Results; Co. Reports ‘Study Conducted with Arizona Liver Health Met Primary Endpoint’